PH12016501686A1 - Pharmaceutical compositions of sitagliptin - Google Patents
Pharmaceutical compositions of sitagliptinInfo
- Publication number
- PH12016501686A1 PH12016501686A1 PH12016501686A PH12016501686A PH12016501686A1 PH 12016501686 A1 PH12016501686 A1 PH 12016501686A1 PH 12016501686 A PH12016501686 A PH 12016501686A PH 12016501686 A PH12016501686 A PH 12016501686A PH 12016501686 A1 PH12016501686 A1 PH 12016501686A1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical compositions
- sitagliptin
- processes
- preparation
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN651MU2014 IN2014MU00651A (2) | 2014-02-25 | 2014-02-25 | |
| PCT/IN2015/000104 WO2015128877A1 (en) | 2014-02-25 | 2015-02-25 | Pharmaceutical compositions of sitagliptin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12016501686A1 true PH12016501686A1 (en) | 2016-10-03 |
Family
ID=53181316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016501686A PH12016501686A1 (en) | 2014-02-25 | 2016-08-25 | Pharmaceutical compositions of sitagliptin |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10925871B2 (2) |
| IN (1) | IN2014MU00651A (2) |
| PH (1) | PH12016501686A1 (2) |
| WO (1) | WO2015128877A1 (2) |
| ZA (1) | ZA201606075B (2) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019087054A1 (en) * | 2017-11-01 | 2019-05-09 | Zenvision Pharma Llp | Novel pharmaceutical composition comprising dpp-4 inhibitor, alpha-lipoic acid and vitamin b12 |
| WO2020018034A2 (en) | 2018-04-17 | 2020-01-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Oral pharmaceutical compositions comprising dpp-4 inhibitor |
| CN109893505B (zh) * | 2019-04-18 | 2021-06-29 | 上海海洋大学 | 由天然植物蛋白作为载体制备包含川陈皮素的固体分散体 |
| TR201910633A1 (tr) * | 2019-07-17 | 2021-05-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Si̇taglipti̇n i̇çeren efervesan tablet kompozi̇syonu |
| WO2021076066A1 (en) * | 2019-10-14 | 2021-04-22 | Santa Farma İlaç Sanayi̇ A.Ş. | Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics |
| GR1010089B (el) * | 2020-09-15 | 2021-09-27 | Φαρματεν Α.Β.Ε.Ε. | Στερεη φαρμακοτεχνικη μορφη περιεχουσα σιταγλιπτινη και μεθοδος παρασκευης αυτης |
| CN113143929B (zh) * | 2021-04-15 | 2023-04-07 | 浙江诺得药业有限公司 | 一种西格列汀复方制剂的制备方法 |
| CN113679684B (zh) * | 2021-08-20 | 2023-06-16 | 北京鑫开元医药科技有限公司 | 磷酸西格列汀组合物、磷酸西格列汀片及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| CN100457108C (zh) | 2003-09-02 | 2009-02-04 | 默克公司 | 一种二肽基肽酶iv抑制剂的磷酸盐新晶体 |
| WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| EP1708571A4 (en) | 2004-01-16 | 2009-07-08 | Merck & Co Inc | NEW CRYSTALLINE SALTS OF A DIPEPTIDYLPEPTIDASE IV HEMMER |
| WO2006033848A1 (en) | 2004-09-15 | 2006-03-30 | Merck & Co., Inc. | Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| EP1909776A2 (en) | 2005-07-25 | 2008-04-16 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
| US9034381B2 (en) * | 2005-11-10 | 2015-05-19 | Alphapharm Pty Ltd | Process to control particle size |
| EP2436381A1 (en) | 2006-06-27 | 2012-04-04 | Sandoz AG | Crystallization of hydrohalides of pharmaceutical compounds |
| WO2009084024A2 (en) | 2007-11-02 | 2009-07-09 | Glenmark Generics Limited | A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof |
| EP2599781A1 (en) | 2007-12-20 | 2013-06-05 | Dr. Reddy's Laboratories Ltd. | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof |
| TW201000485A (en) | 2008-03-25 | 2010-01-01 | Teva Pharma | Crystalline forms of sitagliptin phosphate |
| US20090247532A1 (en) | 2008-03-28 | 2009-10-01 | Mae De Ltd. | Crystalline polymorph of sitagliptin phosphate and its preparation |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| PL2586782T5 (pl) | 2008-07-03 | 2018-05-30 | Ratiopharm Gmbh | Krystaliczne sole sitagliptyny |
| US20100069637A1 (en) | 2008-07-29 | 2010-03-18 | Medichem S.A. | CRYSTALLINE SALT FORMS OF A 5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[4,3-a]PYRAZINE DERIVATIVE |
| US8476437B2 (en) | 2008-08-27 | 2013-07-02 | Cadila Healthcare Limited | Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof |
| WO2012131005A1 (en) * | 2011-03-29 | 2012-10-04 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition of sitagliptin |
-
2014
- 2014-02-25 IN IN651MU2014 patent/IN2014MU00651A/en unknown
-
2015
- 2015-02-25 US US15/121,514 patent/US10925871B2/en active Active
- 2015-02-25 WO PCT/IN2015/000104 patent/WO2015128877A1/en not_active Ceased
-
2016
- 2016-08-25 PH PH12016501686A patent/PH12016501686A1/en unknown
- 2016-09-01 ZA ZA2016/06075A patent/ZA201606075B/en unknown
-
2021
- 2021-01-25 US US17/156,809 patent/US20210137920A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015128877A1 (en) | 2015-09-03 |
| US20210137920A1 (en) | 2021-05-13 |
| US10925871B2 (en) | 2021-02-23 |
| IN2014MU00651A (2) | 2015-10-23 |
| US20160367552A1 (en) | 2016-12-22 |
| ZA201606075B (en) | 2017-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004557B (en) | Modulatory polynucleotides | |
| GEP20217239B (en) | Pharmaceutical composition | |
| MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
| ZA201802199B (en) | Pharmaceutical compositions of il-2 | |
| SI3116491T1 (sl) | Farmacevtski sestavki terapevtsko aktivnih spojin | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| GEP20217240B (en) | Pharmaceutical composition | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| IL273259A (en) | Production of pharmaceutical preparations | |
| ZA201807125B (en) | Pharmaceutical composition of dapagliflozin | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| IN2013MU03641A (2) | ||
| ZA201606075B (en) | Pharmaceutical compositions of sitagliptin | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| IN2014CH00840A (2) | ||
| PT3223796T (pt) | Composições farmacêuticas, preparação e suas utilizações | |
| EP3493808A4 (en) | PHARMACEUTICAL COMPOSITIONS OF IBRUTINIB | |
| SI3102187T1 (sl) | Stabilne farmacevtske sestave, ki vsebujejo sitagliptin v obliki tablet s takojšnjim sproščanjem | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| NZ721832A (en) | Solid forms of tenofovir | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| IN2014CH01391A (2) | ||
| GB2569616B (en) | Sustained release oral pharmaceutical compositions of dicycloverine | |
| IN2013CH05770A (2) | ||
| GB201714241D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies |